Key clinical point: Clobetasol propionate 0.025% vs 0.05% cream displayed comparable efficacy with a better systemic safety profile in moderate-to-severe psoriasis.

Major finding: At day 28 of twice-daily application, patient proportion with an abnormal adrenocorticotropic hormone stimulation test was numerically lower for 0.025% formulations 5 (20.7%) and 13 (17.2%) than for 0.05% cream (30.0%; P = .320). All treatments caused a comparable decrease in burning/stinging/pruritus scores, whereas Psoriasis Global Assessment success rates were higher for formulations 5 (38.9%) and 13 (36.8%) than for 0.05% cream (30.8%).

Study details: Findings are from a phase 2a, randomized, multicenter, investigator-blinded, 3-arm study involving 88 patients aged 18 years or above with moderate-to-severe psoriasis randomly assigned to clobetasol propionate 0.025% formulation 5, clobetasol propionate 0.025% formulation 13, or clobetasol propionate 0.05% cream.

Disclosures: The study was sponsored by Dr. Reddy’s Laboratories. S Sidgiddi, in addition to owning stocks in the company, declared serving as an employee of Dr. Reddy’s Laboratories along with SMH Naqvi, R Mittal, S Mehta, and A Mane. Some of the authors declared receiving research funds from Dr. Reddy’s Laboratories.

Source: Sidgiddi S et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00591-z.

Key clinical point: Clobetasol propionate 0.025% vs 0.05% cream displayed comparable efficacy with a better systemic safety profile in moderate-to-severe psoriasis.

Major finding: At day 28 of twice-daily application, patient proportion with an abnormal adrenocorticotropic hormone stimulation test was numerically lower for 0.025% formulations 5 (20.7%) and 13 (17.2%) than for 0.05% cream (30.0%; P = .320). All treatments caused a comparable decrease in burning/stinging/pruritus scores, whereas Psoriasis Global Assessment success rates were higher for formulations 5 (38.9%) and 13 (36.8%) than for 0.05% cream (30.8%).

Study details: Findings are from a phase 2a, randomized, multicenter, investigator-blinded, 3-arm study involving 88 patients aged 18 years or above with moderate-to-severe psoriasis randomly assigned to clobetasol propionate 0.025% formulation 5, clobetasol propionate 0.025% formulation 13, or clobetasol propionate 0.05% cream.

Disclosures: The study was sponsored by Dr. Reddy’s Laboratories. S Sidgiddi, in addition to owning stocks in the company, declared serving as an employee of Dr. Reddy’s Laboratories along with SMH Naqvi, R Mittal, S Mehta, and A Mane. Some of the authors declared receiving research funds from Dr. Reddy’s Laboratories.

Source: Sidgiddi S et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00591-z.

Key clinical point: Clobetasol propionate 0.025% vs 0.05% cream displayed comparable efficacy with a better systemic safety profile in moderate-to-severe psoriasis.

Major finding: At day 28 of twice-daily application, patient proportion with an abnormal adrenocorticotropic hormone stimulation test was numerically lower for 0.025% formulations 5 (20.7%) and 13 (17.2%) than for 0.05% cream (30.0%; P = .320). All treatments caused a comparable decrease in burning/stinging/pruritus scores, whereas Psoriasis Global Assessment success rates were higher for formulations 5 (38.9%) and 13 (36.8%) than for 0.05% cream (30.8%).

Study details: Findings are from a phase 2a, randomized, multicenter, investigator-blinded, 3-arm study involving 88 patients aged 18 years or above with moderate-to-severe psoriasis randomly assigned to clobetasol propionate 0.025% formulation 5, clobetasol propionate 0.025% formulation 13, or clobetasol propionate 0.05% cream.

Disclosures: The study was sponsored by Dr. Reddy’s Laboratories. S Sidgiddi, in addition to owning stocks in the company, declared serving as an employee of Dr. Reddy’s Laboratories along with SMH Naqvi, R Mittal, S Mehta, and A Mane. Some of the authors declared receiving research funds from Dr. Reddy’s Laboratories.

Source: Sidgiddi S et al. Dermatol Ther (Heidelb). 2021 Aug 28. doi: 10.1007/s13555-021-00591-z.

Key clinical point: Psoriasis was associated with an unfavorable cardiovascular and venous thromboembolism (VTE) risk profile in patients with pulmonary embolism (PE) but lower in-hospital mortality.

Major finding: Despite patients with PE and psoriasis being younger than those without psoriasis (median age, 68 years vs 72 years; P < .001), those with psoriasis showed a higher prevalence of VTE and traditional cardiovascular risk factors such as obesity, essential arterial hypertension, hyperlipidemia, and diabetes mellitus (all P < .001) but lower in-hospital mortality (11.1% vs 16.0%; P < .001).

Study details: The study evaluated 1,076,384 hospitalized patients with PE, of which 3,145 (0.3%) patients also had psoriasis.

Disclosures: No specific funding was disclosed for the study. JMG disclosed being an editor for a few journals, co-patent holder of resiquimod for treating cutaneous T cell lymphoma, and Board Director for the International Psoriasis Council. Some of the authors declared receiving consultation fees, research grants, or speaker honoraria from various sources.

Source: Keller K et al. Int J Cardiol. 2021 Sep 1. doi: 10.1016/j.ijcard.2021.08.042.

Key clinical point: Psoriasis was associated with an unfavorable cardiovascular and venous thromboembolism (VTE) risk profile in patients with pulmonary embolism (PE) but lower in-hospital mortality.

Major finding: Despite patients with PE and psoriasis being younger than those without psoriasis (median age, 68 years vs 72 years; P < .001), those with psoriasis showed a higher prevalence of VTE and traditional cardiovascular risk factors such as obesity, essential arterial hypertension, hyperlipidemia, and diabetes mellitus (all P < .001) but lower in-hospital mortality (11.1% vs 16.0%; P < .001).

Study details: The study evaluated 1,076,384 hospitalized patients with PE, of which 3,145 (0.3%) patients also had psoriasis.

Disclosures: No specific funding was disclosed for the study. JMG disclosed being an editor for a few journals, co-patent holder of resiquimod for treating cutaneous T cell lymphoma, and Board Director for the International Psoriasis Council. Some of the authors declared receiving consultation fees, research grants, or speaker honoraria from various sources.

Source: Keller K et al. Int J Cardiol. 2021 Sep 1. doi: 10.1016/j.ijcard.2021.08.042.

Key clinical point: Psoriasis was associated with an unfavorable cardiovascular and venous thromboembolism (VTE) risk profile in patients with pulmonary embolism (PE) but lower in-hospital mortality.

Major finding: Despite patients with PE and psoriasis being younger than those without psoriasis (median age, 68 years vs 72 years; P < .001), those with psoriasis showed a higher prevalence of VTE and traditional cardiovascular risk factors such as obesity, essential arterial hypertension, hyperlipidemia, and diabetes mellitus (all P < .001) but lower in-hospital mortality (11.1% vs 16.0%; P < .001).

Study details: The study evaluated 1,076,384 hospitalized patients with PE, of which 3,145 (0.3%) patients also had psoriasis.

Disclosures: No specific funding was disclosed for the study. JMG disclosed being an editor for a few journals, co-patent holder of resiquimod for treating cutaneous T cell lymphoma, and Board Director for the International Psoriasis Council. Some of the authors declared receiving consultation fees, research grants, or speaker honoraria from various sources.

Source: Keller K et al. Int J Cardiol. 2021 Sep 1. doi: 10.1016/j.ijcard.2021.08.042.

Key clinical point: Compared with calcipotriol monotherapy, short-term therapy with a calcipotriol-betamethasone compound formulation was more efficacious with a similar safety profile in patients with plaque psoriasis.

Major finding: Short-term topical sequential therapy with a calcipotriol-betamethasone compound and calcipotriol improved the Psoriasis Area and Severity Index score (mean difference, −0.94; P < .0001) without any significant difference in overall adverse reaction rate (risk ratio, 0.50; P = .10) compared with calcipotriol monotherapy.

Study details: The data come from a meta-analysis of 22 randomized control trials that included a total of 2,832 patients with plaque psoriasis.

Disclosures: The study was funded by Tianjin municipal health and Health Committee. The authors declared no potential conflict of interests.

Source: Ren J et al. Arch Dermatol Res. 2021 Aug 20. doi: 10.1007/s00403-021-02272-5.

Key clinical point: Compared with calcipotriol monotherapy, short-term therapy with a calcipotriol-betamethasone compound formulation was more efficacious with a similar safety profile in patients with plaque psoriasis.

Major finding: Short-term topical sequential therapy with a calcipotriol-betamethasone compound and calcipotriol improved the Psoriasis Area and Severity Index score (mean difference, −0.94; P < .0001) without any significant difference in overall adverse reaction rate (risk ratio, 0.50; P = .10) compared with calcipotriol monotherapy.

Study details: The data come from a meta-analysis of 22 randomized control trials that included a total of 2,832 patients with plaque psoriasis.

Disclosures: The study was funded by Tianjin municipal health and Health Committee. The authors declared no potential conflict of interests.

Source: Ren J et al. Arch Dermatol Res. 2021 Aug 20. doi: 10.1007/s00403-021-02272-5.

Key clinical point: Compared with calcipotriol monotherapy, short-term therapy with a calcipotriol-betamethasone compound formulation was more efficacious with a similar safety profile in patients with plaque psoriasis.

Major finding: Short-term topical sequential therapy with a calcipotriol-betamethasone compound and calcipotriol improved the Psoriasis Area and Severity Index score (mean difference, −0.94; P < .0001) without any significant difference in overall adverse reaction rate (risk ratio, 0.50; P = .10) compared with calcipotriol monotherapy.

Study details: The data come from a meta-analysis of 22 randomized control trials that included a total of 2,832 patients with plaque psoriasis.

Disclosures: The study was funded by Tianjin municipal health and Health Committee. The authors declared no potential conflict of interests.

Source: Ren J et al. Arch Dermatol Res. 2021 Aug 20. doi: 10.1007/s00403-021-02272-5.

Key clinical point: Patients with psoriasis receiving methotrexate therapy were less prone to develop composite cardiovascular outcomes than those receiving retinoids.

Major finding: Methotrexate vs. retinoids was associated with lower risks for composite cardiovascular outcomes (adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI], 0.76-0.94) and all-cause mortality (aHR, 0.75; 95% CI, 0.66-0.85).

Study details: This was a retrospective nationwide cohort study that included 19,797 patients with psoriasis, of which 13,777 and 6,020 patients received MTX and retinoids, respectively.

Disclosures: This study was supported by the Taiwan Ministry of Science and Technology. The authors declared no potential conflict of interests.

Source: Tsai MH et al. Clin Epidemiol. 2021 Aug 11. doi: 10.2147/CLEP.S305126.

Key clinical point: Patients with psoriasis receiving methotrexate therapy were less prone to develop composite cardiovascular outcomes than those receiving retinoids.

Major finding: Methotrexate vs. retinoids was associated with lower risks for composite cardiovascular outcomes (adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI], 0.76-0.94) and all-cause mortality (aHR, 0.75; 95% CI, 0.66-0.85).

Study details: This was a retrospective nationwide cohort study that included 19,797 patients with psoriasis, of which 13,777 and 6,020 patients received MTX and retinoids, respectively.

Disclosures: This study was supported by the Taiwan Ministry of Science and Technology. The authors declared no potential conflict of interests.

Source: Tsai MH et al. Clin Epidemiol. 2021 Aug 11. doi: 10.2147/CLEP.S305126.

Key clinical point: Patients with psoriasis receiving methotrexate therapy were less prone to develop composite cardiovascular outcomes than those receiving retinoids.

Major finding: Methotrexate vs. retinoids was associated with lower risks for composite cardiovascular outcomes (adjusted hazard ratio [aHR], 0.84; 95% confidence interval [CI], 0.76-0.94) and all-cause mortality (aHR, 0.75; 95% CI, 0.66-0.85).

Study details: This was a retrospective nationwide cohort study that included 19,797 patients with psoriasis, of which 13,777 and 6,020 patients received MTX and retinoids, respectively.

Disclosures: This study was supported by the Taiwan Ministry of Science and Technology. The authors declared no potential conflict of interests.

Source: Tsai MH et al. Clin Epidemiol. 2021 Aug 11. doi: 10.2147/CLEP.S305126.

Key clinical point: Apremilast significantly improved nail-specific quality of life, clinical signs, and ultrasound parameters, along with a consistent safety profile in patients with psoriasis and predominant nail disease.

Major finding: At 52 weeks, 52% of patients had Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) Patient Benefit Index global weighted score of 2 or more. Median NAPPA Quality of Life and fingernail Nail Psoriasis Severity Index (NAPSI) improved by 57% and 53%, respectively. Ultrasound parameters improved from 16 weeks onward. Adverse events were mostly mild and transient.

Study details: This was a prospective cohort study that included 45 adult patients with plaque and nail psoriasis and a fingernail NAPSI score of 12 or more who were treated with apremilast 30 mg twice a day for 52 weeks.

Disclosures: This study was supported by Amgen. Dr. Muñoz-Santos, Dr. Vidal, and Dr. Guilabert declared receiving personal fees, presentation honoraria, or travel expenses from various sources including Amgen.

Source: Muñoz-Santos C et al. J Dermatol. 2021 Aug 12. doi: 10.1111/1346-8138.16074.

Key clinical point: Apremilast significantly improved nail-specific quality of life, clinical signs, and ultrasound parameters, along with a consistent safety profile in patients with psoriasis and predominant nail disease.

Major finding: At 52 weeks, 52% of patients had Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) Patient Benefit Index global weighted score of 2 or more. Median NAPPA Quality of Life and fingernail Nail Psoriasis Severity Index (NAPSI) improved by 57% and 53%, respectively. Ultrasound parameters improved from 16 weeks onward. Adverse events were mostly mild and transient.

Study details: This was a prospective cohort study that included 45 adult patients with plaque and nail psoriasis and a fingernail NAPSI score of 12 or more who were treated with apremilast 30 mg twice a day for 52 weeks.

Disclosures: This study was supported by Amgen. Dr. Muñoz-Santos, Dr. Vidal, and Dr. Guilabert declared receiving personal fees, presentation honoraria, or travel expenses from various sources including Amgen.

Source: Muñoz-Santos C et al. J Dermatol. 2021 Aug 12. doi: 10.1111/1346-8138.16074.

Key clinical point: Apremilast significantly improved nail-specific quality of life, clinical signs, and ultrasound parameters, along with a consistent safety profile in patients with psoriasis and predominant nail disease.

Major finding: At 52 weeks, 52% of patients had Nail Assessment in Psoriasis and Psoriatic Arthritis (NAPPA) Patient Benefit Index global weighted score of 2 or more. Median NAPPA Quality of Life and fingernail Nail Psoriasis Severity Index (NAPSI) improved by 57% and 53%, respectively. Ultrasound parameters improved from 16 weeks onward. Adverse events were mostly mild and transient.

Study details: This was a prospective cohort study that included 45 adult patients with plaque and nail psoriasis and a fingernail NAPSI score of 12 or more who were treated with apremilast 30 mg twice a day for 52 weeks.

Disclosures: This study was supported by Amgen. Dr. Muñoz-Santos, Dr. Vidal, and Dr. Guilabert declared receiving personal fees, presentation honoraria, or travel expenses from various sources including Amgen.

Source: Muñoz-Santos C et al. J Dermatol. 2021 Aug 12. doi: 10.1111/1346-8138.16074.

Key clinical point: Anxiety and depressive symptoms, individually or in concurrence, were prevalent among patients with plaque psoriasis. Depressive symptoms seemed to have more impact on psoriasis and patient health-related quality of life (QoL) than anxiety symptoms.

Major finding: Overall, 27% and 22% of patients had symptoms of anxiety and depression, respectively, whereas 14% of patients had both. Patients with vs. without depression had significantly higher itch (6.0 vs 3.0; P = .009) and skin pain (2.5 vs 1.0; P = .01) numeric rating scale (NRS) score. However, itch (P = .42) and skin pain (P = .06) NRS were not significantly different in patients with vs. without anxiety.

Study details: Findings are from an analysis of 73 Japanese patients aged 18 years or more with plaque psoriasis without peripheral arthritis symptoms from the ProLOGUE study.

Disclosures: The study was sponsored by Kyowa Kirin Co., Ltd. Dr. Ohata, Dr. Murotani, and Dr. Imafuku declared receiving grants, personal fees, meeting and travel expenses, or nonfinancial support from various sources, including Kyowa Kirin Co., Ltd. Dr. Kanai and Mr. Kitabayashi reported being employees of Kyowa Kirin Co. Ltd.

Source: Ohata C et al. J Eur Acad Dermatol Venereol. 2021 Aug 21. doi: 10.1111/jdv.17621.

Key clinical point: Anxiety and depressive symptoms, individually or in concurrence, were prevalent among patients with plaque psoriasis. Depressive symptoms seemed to have more impact on psoriasis and patient health-related quality of life (QoL) than anxiety symptoms.

Major finding: Overall, 27% and 22% of patients had symptoms of anxiety and depression, respectively, whereas 14% of patients had both. Patients with vs. without depression had significantly higher itch (6.0 vs 3.0; P = .009) and skin pain (2.5 vs 1.0; P = .01) numeric rating scale (NRS) score. However, itch (P = .42) and skin pain (P = .06) NRS were not significantly different in patients with vs. without anxiety.

Study details: Findings are from an analysis of 73 Japanese patients aged 18 years or more with plaque psoriasis without peripheral arthritis symptoms from the ProLOGUE study.

Disclosures: The study was sponsored by Kyowa Kirin Co., Ltd. Dr. Ohata, Dr. Murotani, and Dr. Imafuku declared receiving grants, personal fees, meeting and travel expenses, or nonfinancial support from various sources, including Kyowa Kirin Co., Ltd. Dr. Kanai and Mr. Kitabayashi reported being employees of Kyowa Kirin Co. Ltd.

Source: Ohata C et al. J Eur Acad Dermatol Venereol. 2021 Aug 21. doi: 10.1111/jdv.17621.

Key clinical point: Anxiety and depressive symptoms, individually or in concurrence, were prevalent among patients with plaque psoriasis. Depressive symptoms seemed to have more impact on psoriasis and patient health-related quality of life (QoL) than anxiety symptoms.

Major finding: Overall, 27% and 22% of patients had symptoms of anxiety and depression, respectively, whereas 14% of patients had both. Patients with vs. without depression had significantly higher itch (6.0 vs 3.0; P = .009) and skin pain (2.5 vs 1.0; P = .01) numeric rating scale (NRS) score. However, itch (P = .42) and skin pain (P = .06) NRS were not significantly different in patients with vs. without anxiety.

Study details: Findings are from an analysis of 73 Japanese patients aged 18 years or more with plaque psoriasis without peripheral arthritis symptoms from the ProLOGUE study.

Disclosures: The study was sponsored by Kyowa Kirin Co., Ltd. Dr. Ohata, Dr. Murotani, and Dr. Imafuku declared receiving grants, personal fees, meeting and travel expenses, or nonfinancial support from various sources, including Kyowa Kirin Co., Ltd. Dr. Kanai and Mr. Kitabayashi reported being employees of Kyowa Kirin Co. Ltd.

Source: Ohata C et al. J Eur Acad Dermatol Venereol. 2021 Aug 21. doi: 10.1111/jdv.17621.

Key clinical point: Compared with enzalutamide, abiraterone was associated with a 31% higher risk for myocardial infarction or stroke in patients with metastatic prostate cancer.

Major finding: Abiraterone vs. enzalutamide was associated with an increased risk for myocardial infarction or stroke (hazard ratio [HR], 1.31; P = .01). A higher risk for stroke was observed in patients who received abiraterone vs enzalutamide (HR, 1.52; P = .008). No difference was seen in the risk for myocardial infarction between the 2 treatments (P = .92).

Study details: A retrospective study of 6,294 patients with metastatic prostate cancer who received androgen deprivation therapy with either abiraterone or enzalutamide.

Disclosures: No funding source was identified for this study. The authors received research funding, advisory/speaker fees, and/or honoraria from various sources.

Source: Kulkarni AA et al. ESMO Open. 2021 Sep 9. doi: 10.1016/j.esmoop.2021.100261.

Key clinical point: Compared with enzalutamide, abiraterone was associated with a 31% higher risk for myocardial infarction or stroke in patients with metastatic prostate cancer.

Major finding: Abiraterone vs. enzalutamide was associated with an increased risk for myocardial infarction or stroke (hazard ratio [HR], 1.31; P = .01). A higher risk for stroke was observed in patients who received abiraterone vs enzalutamide (HR, 1.52; P = .008). No difference was seen in the risk for myocardial infarction between the 2 treatments (P = .92).

Study details: A retrospective study of 6,294 patients with metastatic prostate cancer who received androgen deprivation therapy with either abiraterone or enzalutamide.

Disclosures: No funding source was identified for this study. The authors received research funding, advisory/speaker fees, and/or honoraria from various sources.

Source: Kulkarni AA et al. ESMO Open. 2021 Sep 9. doi: 10.1016/j.esmoop.2021.100261.

Key clinical point: Compared with enzalutamide, abiraterone was associated with a 31% higher risk for myocardial infarction or stroke in patients with metastatic prostate cancer.

Major finding: Abiraterone vs. enzalutamide was associated with an increased risk for myocardial infarction or stroke (hazard ratio [HR], 1.31; P = .01). A higher risk for stroke was observed in patients who received abiraterone vs enzalutamide (HR, 1.52; P = .008). No difference was seen in the risk for myocardial infarction between the 2 treatments (P = .92).

Study details: A retrospective study of 6,294 patients with metastatic prostate cancer who received androgen deprivation therapy with either abiraterone or enzalutamide.

Disclosures: No funding source was identified for this study. The authors received research funding, advisory/speaker fees, and/or honoraria from various sources.

Source: Kulkarni AA et al. ESMO Open. 2021 Sep 9. doi: 10.1016/j.esmoop.2021.100261.

Key clinical point: In patients with high-risk prostate cancer undergoing radical prostatectomy, persistent prostate-specific antigen (PSA) is associated with poor oncological outcomes. Early salvage radiotherapy with or without androgen deprivation therapy (ADT) improves survival in patients with persistent PSA.

Major finding: In patients with persistent vs. undetectable PSA, estimated clinical progression-free survival (63.8% vs 93.5%; P < .0001) and overall survival (OS; 54.0% vs 83.2%; P < .0001) were significantly lower at 10 years. In patients with persistent PSA, ADT alone vs salvage radiotherapy was associated with a higher risk for worse OS (hazard ratio, 4.7; P < .0001).

Study details: A retrospective study of 414 consecutive patients with high-risk prostate cancer who underwent radical prostatectomy; 125 patients had persistent PSA.

Disclosures: The study did not receive any funding. The authors declared no competing interests.

Source: Milonas D et al. Clin Transl Oncol. 2021 Aug 28. doi: 10.1007/s12094-021-02700-y.

Key clinical point: In patients with high-risk prostate cancer undergoing radical prostatectomy, persistent prostate-specific antigen (PSA) is associated with poor oncological outcomes. Early salvage radiotherapy with or without androgen deprivation therapy (ADT) improves survival in patients with persistent PSA.

Major finding: In patients with persistent vs. undetectable PSA, estimated clinical progression-free survival (63.8% vs 93.5%; P < .0001) and overall survival (OS; 54.0% vs 83.2%; P < .0001) were significantly lower at 10 years. In patients with persistent PSA, ADT alone vs salvage radiotherapy was associated with a higher risk for worse OS (hazard ratio, 4.7; P < .0001).

Study details: A retrospective study of 414 consecutive patients with high-risk prostate cancer who underwent radical prostatectomy; 125 patients had persistent PSA.

Disclosures: The study did not receive any funding. The authors declared no competing interests.

Source: Milonas D et al. Clin Transl Oncol. 2021 Aug 28. doi: 10.1007/s12094-021-02700-y.

Key clinical point: In patients with high-risk prostate cancer undergoing radical prostatectomy, persistent prostate-specific antigen (PSA) is associated with poor oncological outcomes. Early salvage radiotherapy with or without androgen deprivation therapy (ADT) improves survival in patients with persistent PSA.

Major finding: In patients with persistent vs. undetectable PSA, estimated clinical progression-free survival (63.8% vs 93.5%; P < .0001) and overall survival (OS; 54.0% vs 83.2%; P < .0001) were significantly lower at 10 years. In patients with persistent PSA, ADT alone vs salvage radiotherapy was associated with a higher risk for worse OS (hazard ratio, 4.7; P < .0001).

Study details: A retrospective study of 414 consecutive patients with high-risk prostate cancer who underwent radical prostatectomy; 125 patients had persistent PSA.

Disclosures: The study did not receive any funding. The authors declared no competing interests.

Source: Milonas D et al. Clin Transl Oncol. 2021 Aug 28. doi: 10.1007/s12094-021-02700-y.

Key clinical point: High-intensity interval training (HIIT) improves cardiorespiratory fitness levels and lowers prostate-specific antigen (PSA) levels, PSA velocity, and prostate cancer cell growth in patients with localized prostate cancer undergoing active surveillance.

Major finding: The peak oxygen consumption increased by 0.9 mL/kg/minute in the HIIT group and decreased by 0.5 mL/kg/minute in the usual-care group (P = .01). Compared with the usual care, HIIT was associated with a significant decrease in PSA levels (P = .04), PSA velocity (P = .04), and growth of prostate cancer cell line (P = .02).

Study details: Phase 2 ERASE study of 52 men with prostate cancer undergoing active surveillance who were randomly assigned to HIIT or to usual care.

Disclosures: This study was supported by Canadian Institutes of Health Research and Prostate Cancer Canada. The authors reported no conflict of interests.

Source: Kang DW et al. JAMA Oncol. 2021 Aug 19. doi: 10.1001/jamaoncol.2021.3067.

Key clinical point: High-intensity interval training (HIIT) improves cardiorespiratory fitness levels and lowers prostate-specific antigen (PSA) levels, PSA velocity, and prostate cancer cell growth in patients with localized prostate cancer undergoing active surveillance.

Major finding: The peak oxygen consumption increased by 0.9 mL/kg/minute in the HIIT group and decreased by 0.5 mL/kg/minute in the usual-care group (P = .01). Compared with the usual care, HIIT was associated with a significant decrease in PSA levels (P = .04), PSA velocity (P = .04), and growth of prostate cancer cell line (P = .02).

Study details: Phase 2 ERASE study of 52 men with prostate cancer undergoing active surveillance who were randomly assigned to HIIT or to usual care.

Disclosures: This study was supported by Canadian Institutes of Health Research and Prostate Cancer Canada. The authors reported no conflict of interests.

Source: Kang DW et al. JAMA Oncol. 2021 Aug 19. doi: 10.1001/jamaoncol.2021.3067.

Key clinical point: High-intensity interval training (HIIT) improves cardiorespiratory fitness levels and lowers prostate-specific antigen (PSA) levels, PSA velocity, and prostate cancer cell growth in patients with localized prostate cancer undergoing active surveillance.

Major finding: The peak oxygen consumption increased by 0.9 mL/kg/minute in the HIIT group and decreased by 0.5 mL/kg/minute in the usual-care group (P = .01). Compared with the usual care, HIIT was associated with a significant decrease in PSA levels (P = .04), PSA velocity (P = .04), and growth of prostate cancer cell line (P = .02).

Study details: Phase 2 ERASE study of 52 men with prostate cancer undergoing active surveillance who were randomly assigned to HIIT or to usual care.

Disclosures: This study was supported by Canadian Institutes of Health Research and Prostate Cancer Canada. The authors reported no conflict of interests.

Source: Kang DW et al. JAMA Oncol. 2021 Aug 19. doi: 10.1001/jamaoncol.2021.3067.

Key clinical point: Radium-223 in combination with enzalutamide is safe in the long term and improves second-line prostate-specific antigen (PSA)-progression-free survival (PFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) vs. enzalutamide alone.

Major finding: Median follow-up was 22 months. Radium-223 plus enzalutamide vs. enzalutamide alone did not improve median overall survival (P = .73), PSA-PFS (P = .97), and radiographic PFS (P= .96). Radium-223 plus enzalutamide vs enzalutamide alone significantly improved second-line PSA-PFS (18.7 months vs 8.41 months; P = .033).

Study details: A phase 2 randomized trial of 47 patients with mCRPC randomly assigned to receive either radium-223 dichloride with enzalutamide or enzalutamide alone.

Disclosures: The study was supported by the University of Utah. The authors did not disclose any conflict of interests.

Source: Maughan BL et al. Oncologist. 2021 Aug 22. doi: 10.1002/onco.13949.

Key clinical point: Radium-223 in combination with enzalutamide is safe in the long term and improves second-line prostate-specific antigen (PSA)-progression-free survival (PFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) vs. enzalutamide alone.

Major finding: Median follow-up was 22 months. Radium-223 plus enzalutamide vs. enzalutamide alone did not improve median overall survival (P = .73), PSA-PFS (P = .97), and radiographic PFS (P= .96). Radium-223 plus enzalutamide vs enzalutamide alone significantly improved second-line PSA-PFS (18.7 months vs 8.41 months; P = .033).

Study details: A phase 2 randomized trial of 47 patients with mCRPC randomly assigned to receive either radium-223 dichloride with enzalutamide or enzalutamide alone.

Disclosures: The study was supported by the University of Utah. The authors did not disclose any conflict of interests.

Source: Maughan BL et al. Oncologist. 2021 Aug 22. doi: 10.1002/onco.13949.

Key clinical point: Radium-223 in combination with enzalutamide is safe in the long term and improves second-line prostate-specific antigen (PSA)-progression-free survival (PFS) in patients with metastatic castration-resistant prostate cancer (mCRPC) vs. enzalutamide alone.

Major finding: Median follow-up was 22 months. Radium-223 plus enzalutamide vs. enzalutamide alone did not improve median overall survival (P = .73), PSA-PFS (P = .97), and radiographic PFS (P= .96). Radium-223 plus enzalutamide vs enzalutamide alone significantly improved second-line PSA-PFS (18.7 months vs 8.41 months; P = .033).

Study details: A phase 2 randomized trial of 47 patients with mCRPC randomly assigned to receive either radium-223 dichloride with enzalutamide or enzalutamide alone.

Disclosures: The study was supported by the University of Utah. The authors did not disclose any conflict of interests.

Source: Maughan BL et al. Oncologist. 2021 Aug 22. doi: 10.1002/onco.13949.